Skip to main content

Nektar Therapeutics

corporate_fare Company Profile

Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed NKTR - Latest Insights

NKTR
Apr 24, 2026, 4:16 PM EDT
Filing Type: DEFA14A
Importance Score:
7
NKTR
Apr 23, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
9
NKTR
Apr 23, 2026, 6:02 AM EDT
Filing Type: 424B5
Importance Score:
8
NKTR
Apr 21, 2026, 9:31 PM EDT
Source: Reuters
Importance Score:
8
NKTR
Apr 20, 2026, 5:00 PM EDT
Filing Type: 424B5
Importance Score:
8
NKTR
Apr 20, 2026, 4:58 PM EDT
Filing Type: 8-K
Importance Score:
8
NKTR
Apr 20, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
NKTR
Apr 20, 2026, 8:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
NKTR
Mar 12, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
7
NKTR
Mar 12, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
8
NKTR
Feb 12, 2026, 8:23 PM EST
Filing Type: 8-K
Importance Score:
9
NKTR
Feb 12, 2026, 6:40 PM EST
Filing Type: 424B5
Importance Score:
9
NKTR
Feb 10, 2026, 4:24 PM EST
Filing Type: 424B5
Importance Score:
8
NKTR
Feb 10, 2026, 4:21 PM EST
Filing Type: 8-K
Importance Score:
8
NKTR
Feb 10, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
8